MaxCyte (MXCT) vs OneMedNet (ONMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MaxCyte (MXCT) has outperformed OneMedNet (ONMD) over the past year, losing 18.0% versus a loss of 65.2%. Over five years, MXCT leads with a -85.9% price change compared with -95.3% for ONMD. MaxCyte is the larger company by market cap ($141.5 million vs $29.1 million), about 4.9 times the size, while OneMedNet is growing revenue faster (+111.4% vs -14.5%).
MaxCyte converts more of its revenue into profit, with a net margin of -135.1% versus -206.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MXCT | ONMD |
|---|---|---|
| Share price | $1.37 | $4.70 |
| Market cap | $141.45M | $29.15M |
| 1-day change | +7.03% | +4.21% |
| YTD return | -11.61% | -57.27% |
| 1-year return | -17.96% | -65.19% |
| 5-year return | -85.92% | -95.33% |
| EPS (TTM) | $-0.26 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $33.03M | $1.36M |
| Revenue growth (YoY) | -14.50% | +111.35% |
| Net income (latest FY) | $-44.63M | $-2.80M |
| Gross margin | 81.16% | -37.01% |
| Operating margin | -157.14% | -711.33% |
| Net margin | -135.14% | -206.11% |
| 52-week high | $1.80 | $23.00 |
| 52-week low | $0.643 | $3.61 |
| Distance from 52-week high | -23.89% | -79.57% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +200.00% | — |
| Average volume | 1.04M | 38.62K |
| Shares outstanding | 103.25M | 6.20M |
| Employees | 91 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MaxCyte is about 4.9 times larger than OneMedNet by market value ($141.45M vs $29.15M).
- MXCT has outperformed ONMD by 47.2 percentage points over the past year.
- MaxCyte is more profitable, keeping -135.1 cents of every revenue dollar as net income versus -206.1 cents for OneMedNet.
- OneMedNet grew revenue faster in its latest fiscal year (+111.35% vs -14.50%).
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees
About OneMedNet
ONMD stock →OneMedNet Corporation, a healthcare software company, provides digital medical image management, exchange, and sharing solutions in the Americas, Europe, and the Middle East. It offers iRWD, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, contract research organizations, and artificial intelligence markets markets.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 22 employees
MXCT vs ONMD FAQ
Which is bigger, MaxCyte or OneMedNet?
MaxCyte (MXCT) is larger, with a market capitalization of $141.45M compared with $29.15M for OneMedNet (ONMD).
Which stock has performed better over the past year, MXCT or ONMD?
MXCT returned -17.96% over the past 12 months, compared with -65.19% for ONMD (price return, excluding dividends). Past performance does not predict future results.
Are MaxCyte and OneMedNet in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.